Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 83Neoplasms 79Colorectal Neoplasms 68Neoplasm Metastasis 66Prostatic Neoplasms 62Leukemia, Myeloid, Acute 61Ovarian Neoplasms 58Recurrence 56Pancreatic Neoplasms 56Multiple Myeloma 52Melanoma 41Lung Neoplasms 38Glioblastoma 38Triple Negative Breast Neoplasms 36Squamous Cell Carcinoma of Head and Neck 35Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Myelodysplastic Syndromes 26Carcinoma, Hepatocellular 26Lymphoma, B-Cell 25Advanced Solid Tumor 25Sarcoma 24Leukemia, Lymphocytic, Chronic, B-Cell 24

Interventions

pembrolizumab 1Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lethal Congenital Contracture Syndrome 2 × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡